"Meditab Holdings Ltd, Mauritius, a wholly owned subsidiary of the company, has entered into a definitive agreement to sell its entire 48.22 per cent equity interest in Jiangsu Cdymax Pharmaceuticals Co Ltd, China to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of USD 18.5 million," Cipla said in a filing to the BSE.

The closing of the transaction is subject to receipt of applicable regulatory approvals in China, it added.      

Shares of Cipla were on Wednesday trading at Rs 648 per scrip in the afternoon trade on the BSE, up 1.27 percent from its previous clsoe.

Latest News  from Business News Desk